Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Let your light shine down.

Science immunology·2026

Same author

A novel hyperactive <i>BCR::ABL1</i> <sup><i>e6a3</i></sup> variant confers resistance to combined asciminib plus ponatinib therapy.

medRxiv : the preprint server for health sciences·2026

Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026

Same author

Blastic Plasmacytoid Dendritic Cell Neoplasm: Updates in Diagnostic and Molecular Pathology.

Surgical pathology clinics·2026

Same author

Structural variation tunes apoptotic responses to drive immune escape in melanoma.

Science immunology·2026

Same author

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.

bioRxiv : the preprint server for biology·2025

Same journal

Evolution and development of innate immune memory.

Science immunology·2026

Same journal

The evolving biology of T cell memory: A dynamic continuum of function and persistence.

Science immunology·2026

Same journal

Memories that endure.

Science immunology·2026

Same journal

ILC2s shoot 4 making 13s.

Science immunology·2026

Same journal

Molecular and tissue regulation of memory B cells.

Science immunology·2026

Same journal

A breath of fresh AIR in novel CAR T cell design.

Science immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Constant attack on T cell lymphomas.

Gabriel K Griffin¹

¹Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Science Immunology

|December 3, 2017

Summary

This summary is machine-generated.

Researchers developed a new CAR-T cell therapy targeting T cell lymphoma. This approach selectively targets the T cell receptor β-chain constant region 1 for improved treatment.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Related Experiment Videos

Last Updated: Feb 17, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Area of Science:

Immunology
Oncology
Cellular Therapy

Background:

T cell lymphoma is a challenging malignancy with limited treatment options.
Current therapies often lack specificity, leading to off-target effects.
Chimeric antigen receptor T cell (CAR-T) therapy has shown promise in hematologic malignancies.

Discussion:

This study presents a novel CAR-T cell strategy for T cell lymphoma.
The therapy is engineered to target the T cell receptor β-chain constant region 1 (TRBC1).
TRBC1 is a specific marker present on malignant T cells.

Key Insights:

Successful generation of CAR-T cells targeting TRBC1.
Demonstrates proof-of-principle for TRBC1-specific CAR-T cell therapy.
Highlights the potential for selective targeting of T cell malignancies.

Outlook:

Further preclinical and clinical studies are warranted to evaluate efficacy and safety.
This approach may offer a new therapeutic avenue for T cell lymphoma patients.
Potential for broader application in other T cell-mediated diseases.